The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study.

OBJECTIVES To determine factors associated with survival and to assess the relative strength of CD4 cell count and HIV-1 RNA in predicting survival in a cohort of HIV-1-infected women. DESIGN Prospective cohort, enrolled during 1994-1995, with median follow-up of 29 months RESULTS Of 1769 HIV-infected women 252 died. In multivariate analyses, lower CD4 cell count, higher quantitative plasma HIV-1 RNA, and the presence of a self-reported AIDS-defining (Class C) condition were significantly associated with shorter survival: the relative hazard (RH) of dying was 1.17, 3.27, and 8.46, respectively for women with baseline CD4 cell count of 200-349, 50-199, and < 50 x 10(6) cells/l, compared with women with CD4 cell count of > or = 350 x 10(6) cells/l. Compared with women with HIV-1 RNA levels of < 4000 copies/ml plasma, the RH of dying for women with baseline quantitative HIV-1 RNA measurements of 4000-20,000, 20,000-100,000, 100,000-500,000 and > 500,000 copies/ml, was 2.19, 2.17, 3.16, and 7.25, respectively. CD4 cell count had as strong a prognostic value as HIV-1 RNA level, particularly among participants with more advanced immunodeficiency. When the analysis was adjusted to eliminate the distortion created by having disproportionately sized strata of the categorized variables, the relative hazard of death associated with CD4 cell count became even larger in comparison with that for HIV-1 RNA. Eliminating from the analysis all follow-up time during which participants could have received highly active antiretroviral therapy did not change these findings. Age was not a predictor of survival after adjustment for covariates. CONCLUSIONS CD4 cell count and HIV-1 RNA had similar prognostic value in this cohort of HIV-1-infected women. Even in the presence of a low viral burden, a substantially decreased CD4 cell count remained a strong predictor of mortality.

[1]  J. Chmiel,et al.  Survival from early, intermediate, and late stages of HIV infection. , 1996, JAMA.

[2]  D. Burke,et al.  Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women. , 1997, The Journal of infectious diseases.

[3]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[4]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[5]  R. Chaisson,et al.  Race, sex, drug use, and progression of human immunodeficiency virus disease. , 1995, The New England journal of medicine.

[6]  J M Taylor,et al.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. , 1990, The New England journal of medicine.

[7]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[8]  K. Anastos,et al.  Measurement of human immunodeficiency virus (HIV) type 1 RNA load distinguishes progressive infection from nonprogressive HIV-1 infection in men and women. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Steve Kaye,et al.  HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial , 1997, The Lancet.

[10]  J. Phair,et al.  Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. , 1987, The New England journal of medicine.

[11]  J. Cacioppo,et al.  Postmenopausal Hormone Replacement: Effects on Autonomic, Neuroendocrine, and Immune Reactivity to Brief Psychological Stressors , 1998, Psychosomatic medicine.

[12]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[13]  I Spijkerman,et al.  AIDS prognosis based on HIV‐1 RNA, CD4+ T‐cell count and function: markers with reciprocal predictive value over time after seroconversion , 1997, AIDS.

[14]  G. Rutherford,et al.  Survival trends for patients with AIDS. , 1990, JAMA.

[15]  H. Ullum,et al.  The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection , 1998, AIDS.

[16]  A. Phillips,et al.  Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. , 1996, Genitourinary medicine.

[17]  D. Harrington,et al.  Regression Splines in the Cox Model with Application to Covariate Effects in Liver Disease , 1990 .

[18]  D. Cooper,et al.  Survival of patients with the acquired immunodeficiency syndrome in Australia , 1989, The Medical journal of Australia.

[19]  P. Kvale,et al.  Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia , 1996, Journal of clinical microbiology.

[20]  J. Schroeder,et al.  Comparison of Two Measures of Human Immunodeficiency Virus (HIV) Type 1 Load in HIV Risk Groups , 1998, Journal of Clinical Microbiology.

[21]  Richard D Moore,et al.  Lack of sex difference in CD4 to HIV-1 RNA viral load ratio , 1999, The Lancet.

[22]  J. Darbyshire,et al.  Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.